FINWIRES · TerminalLIVE
FINWIRES

最新情報：BioNTechの第1四半期調整後損失が拡大、売上高は減少。2026年の売上高見通しを再確認。

By

-- （第6段落に人員削減計画、最終段落に最近の株価変動に関する情報を追記。） バイオNTech（BNTX）は火曜日、第1四半期の調整後損失が希薄化後1株当たり1.95ユーロ（2.28ドル）となり、前年同期の1.79ユーロの損失から拡大したと発表した。 FactSetが調査したアナリストは1.27ユーロの損失を予想していた。 3月31日締めの四半期の売上高は1億1810万ユーロで、前年同期の1828億ユーロから減少した。 FactSetが調査したアナリストは1億6460万ユーロを予想していた。 同社は2026年の売上高見通しを20億ユーロから23億ユーロに据え置いた。アナリストは22億2000万ユーロを予想している。 同社は、イダー＝オーバーシュタイン、マールブルク、シンガポールの製造拠点に加え、キュアバック社の拠点からも撤退する計画を発表した。これにより、最大約1,860人の雇用が影響を受ける見込みだ。これらの措置は2027年までに完了し、2029年までに年間約5億ユーロのコスト削減が見込まれる。 バイオNTechの株価は火曜日の取引で2.4%下落した。

Price: $96.96, Change: $-2.39, Percent Change: -2.41%

Related Articles

Australia

American Electric Power CEO Says Speed to Market Key Issue in Load Connection

American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%

$AEP
Australia

MGE Energy Q1 Earnings, Revenue Rise

MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%

$MGEE
Research

Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.

$PFE